Stock Quote & Chart

Stock Quote

Change

Volume

Today's Open

Previous Close

Today's High

Today's Low

52 Week High

52 Week Low

Stock Chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Print Page
Email Alerts
RSS Feeds
Contact Us

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Akari TX

Stock Quote & Chart

Stock Quote & Chart

Stock Quote

Stock Chart

LONDON

NEW YORK

EXPANDED ACCESS POLICY

Skip links

Stock Quote & Chart

Stock Quote & Chart

Stock Quote

Stock Chart

Footer

LONDON

NEW YORK

EXPANDED ACCESS POLICY